Advertisement

Topics

Latest "Insception Biosciences Inc" News Stories

22:46 EST 15th November 2018 | BioPortfolio

Here are the most relevant search results for "Insception Biosciences Inc" found in our extensive news archives from over 250 global news sources.

More Information about Insception Biosciences Inc on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Insception Biosciences Inc for you to read. Along with our medical data and news we also list Insception Biosciences Inc Clinical Trials, which are updated daily. BioPortfolio also has a large database of Insception Biosciences Inc Companies for you to search.

Showing "Insception Biosciences" News Articles 1–25 of 1,300+

Thursday 15th November 2018

Shortlisted Nominees announced for the 2018 Bionow Awards

Bionow has the pleasure in announcing the shortlisted nominees for the 2018 Bionow Awards. The Bionow Award Dinner is a highlight of the life sciences calendar and celebrates the world-class scientists and companies that are driving the North of England’s life science sector.Organised by Bionow, an award-winning specialist business development and services company serving the life scien...


Therapix Biosciences Ltd TRPX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryTherapix Biosciences Ltd Therapix, formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix's major product candidates include THX110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX130, for the treatment of mild ...

ACEA Biosciences Inc Medical Equipment Deals and Alliances Profile [Report Updated: 15102018] Prices from USD $250

SummaryACEA Biosciences Inc ACEA is a biotechnology company that development and commercialization of cell analysis instruments for life science research and clinical diagnostics. The company's products include impedancebased, labelfree, and realtime cell analysis systems, benchtop flow cytometers, RTCA SP instruments, RTCA HT instrument and RTCA MP instrument, among others. ACEA's products are us...


Solid Biosciences: A Classic Story Of Opportunistic Investing

Pressure BioSciences posts 3Q revenue from new scientific services group, lowers operating expenses

The company's novel Ultra Shear Technology has wide potential uses in the beverage, food, pharmaceutical, industrial ink, retail and cosmetics industry

Arix Biosciences hails phase I success of investee company Pharmaxis

Arix is a cornerstone investor in the ASX life sciences group

Nashville Biosciences Enters into Agreement with BC Platforms' Global Biobank Platform

ZURICH and BOSTON, November 15, 2018 /PRNewswire/ -- BC Platforms, a world leader in secure genomic data management and analytics, announces an agreement with Nashville Read more...

Wednesday 14th November 2018

BTS Research Appoints Mark Crane as Vice President, Business Development

BTS Research, a preclinical services Contract Research Organization, is delighted to announce the addition of

Amarillo Biosciences Inc AMAR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryAmarillo Biosciences Inc ABI is a specialty biopharmaceutical company, which focuses on the development of biologics for the treatment of human and animal diseases. It develops innovative therapeutic candidates for the treatment of human disease indications such as influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Its product portfolio inc...

INTEGRA named Pipetting Company of the Year

Consulting company Frost & Sullivan has presented INTEGRA Biosciences with the 2018 Global Laboratory Pipetting Company of the Year award, recognising its products as innovative, revolutionary and able to fulfil the needs of customers. INTEGRA offers an extensive range of manual and automated solutions, providing users with flexibility and small-scale automation that can provide high throughp...

Akers Biosciences Announces Q3 2018 Earnings

Sales of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value THOROFARE, N.J., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reports its financial results for ...

Agilent Completes Acquisition of ACEA Biosciences

Acquisition Brings Together Two Pioneers in Cellular Function and Metabolism Measurements Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. This acquisition brings together two pioneers in cellular function...

Sangamo Therapeutics Inc SGMO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummarySangamo Therapeutics Inc Sangamo, formerly Sangamo BioSciences Inc, is a clinical stage biotechnology company that focuses on the research, development and commercialization of engineered DNAbinding proteins ZFPs for gene regulation, cell therapy and therapeutic genome editing. Its product candidates targets the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome MPS I, fabry disease...

Kuros Biosciences AG KURN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryKuros Biosciences AG Kuros Biosciences is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair...

Solid's manufacturing work allows trial to restart

After a challenging year, it looks as though Solid Biosciences' gene therapy for Duchenne muscular dystrophy is back on track.

MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments

The company has partnered with Precision Biosciences of the US

Tuesday 13th November 2018

Improved mosquito reference genome assembly produced using long-read sequencing

(Bioscribe) A new comprehensive map of mosquito DNA has been assembled using long-read sequencing technology from California-based Pacific Biosciences. The improved reference genome assembly, published in Nature, could help scientists combat the pest and infectious diseases it spreads, including Zika, dengue, chikungunya, and yellow fever.

INTEGRA named ‘2018 Global Laboratory Pipetting Company of the Year’

Frost & Sullivan has presented INTEGRA Biosciences with the ‘2018 Global Laboratory Pipetting Company of the Year’ award, recognizing its products as innovative, revolutionary and able to fulfil the needs of customers. Frost & Sullivan’s transformational health research group conducted extensive research using key benchmarking criteria across two main areas – vision...

Study Demonstrating Accuracy of DecisionDx-Melanoma Prognostic Test Across Melanoma Tissue Sources Presented at the American Society of Dermatopathology 55th Annual Meeting

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced study results showing that the DecisionDx-Melanoma test accurately predicts risk for patients with cutaneous melanoma when using either biopsy or wide local excision (WLE) as the tissue source. Highlights of ...

Cellectar hematology studies exempted from import alert for CLR 131

The FDA has granted Cellectar Biosciences an exemption to the import alert placed on the Centre for Probe Development and Com -More- 

Monday 12th November 2018

Caladrius Biosciences, Inc. 2018 Q3 - Results - Earnings Call Slides

Sunday 11th November 2018

Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, presented final data from the Phase 1b study of ABI-H0731 in...

Coherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference

REDWOOD CITY, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse Healthcare Conference being held in Scottsdale, Arizona on Thursday, November 15 at 9:45 am MST. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences webs...

Selecta Biosciences Inc SELB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummarySelecta Biosciences Inc Selecta Biosciences is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company's pipeline products include SEL212, SEL403, SEL302 and SEL302. It utilizes synthetic vaccine particle SVP technology platform to incorporate a wide range of antigens and immunomodulators, for the development of ...

Kindred Biosciences' (KIN) CEO Richard Chin on Q3 2018 Results - Earnings Call Transcript


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks